Onconetix Inc

NEW
NAS:ONCO (USA)  
$ 0.98 -0.0033 (-0.34%) 10:08 PM EST
At Loss
P/B:
0.02
Market Cap:
$ 3.60M
Enterprise V:
$ 180.00K
Volume:
101.43K
Avg Vol (2M):
1.20M
Trade In:
Volume:
101.43K
At Loss
Avg Vol (2M):
1.20M

Business Description

Onconetix Inc
NAICS : 541713 SIC : 2834
ISIN : US68237Q2030

Total Employee Number:

2
Description
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.
Name Current Vs Industry Vs History
Cash-To-Debt
12.81
Equity-to-Asset
0.79
Debt-to-Equity
0.03
Debt-to-EBITDA
-0.03
Piotroski F-Score
4/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score
-13.97
Distress
Grey
Safe
Beneish M-Score
0.55
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EPS without NRI Growth Rate
86.2
Name Current Vs Industry Vs History
5-Day RSI
40.12
9-Day RSI
30.77
14-Day RSI
27.2
3-1 Month Momentum %
-96.09
6-1 Month Momentum %
-98.24
12-1 Month Momentum %
-99.46

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio
1.41
Quick Ratio
1.37
Cash Ratio
1.21
Days Inventory
366.96
Days Sales Outstanding
36.95
Days Payable
5026.22

Dividend & Buy Back

Name Current Vs Industry Vs History
Shareholder Yield %
202.33
Name Current Vs Industry Vs History
Gross Margin %
79.73
Operating Margin %
-922.86
Net Margin %
-1319.86
EBITDA Margin %
-1245.58
FCF Margin %
-1333.33
OCF Margin %
-1333.33
ROE %
-117.4
ROA %
-49.83
ROIC %
-27.59
3-Year ROIIC %
28.84
ROC (Joel Greenblatt) %
-10971.29
ROCE %
-108.94
Moat Score
3
Tariff Resilience Score
5

GF Valueâ„¢

Onconetix Inc Filings

Filing Date Document Date Form
No Filing Data

Onconetix Inc Stock Events

Financials Calendars
Event Date Price ($)
General meeting for 2026 2026-12-04 11:00 In 159 days
Third quarter earnings results for 2026 2026-11-13 In 137 days
Second quarter earnings results for 2026 2026-08-14 In 46 days
0.1:1 Stock Split 2026-05-21 1.10 (-1.79%)
First quarter earnings results for 2026 2026-05-13 4.08 (+1.95%)
0.2:1 Stock Split 2026-03-25 28.68 (-5.05%)
Annual report for 2025 2026-03-13 28.64 (-7.63%)
General meeting for 2025 2025-12-05 11:00 147.50 (-2.32%)
Third quarter earnings results for 2025 2025-11-13 137.50 (-0.27%)
Second quarter earnings results for 2025 2025-08-14 155.00 (+6.16%)
Show
Entries

Guru Commentaries on NAS:ONCO

No articles.

Articles on Onconetix Inc

No articles.

Headlines

See More
  • 1
No news.
  • 1